|
Editas Medicine
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. History Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures; the name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9. In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, with an IPO that raised $94 million. The company ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Russell 2000 Index
The Russell 2000 Index is a small cap company , small-cap stock market index that makes up the smallest 2,000 stocks in the Russell 3000 Index. It was started by the Frank Russell Company in 1984. The index is maintained by FTSE Russell, a subsidiary of the London Stock Exchange Group (LSEG). Overview The Russell 2000 is by far the most common benchmark for mutual funds that identify themselves as "Market capitalization#Market cap terms, small-cap", while the S&P 500 index is used primarily for large capitalization stocks. It is the most widely quoted measure of the overall performance of small-cap to mid-cap company shares. It is commonly considered an indicator of the U.S. economy due to its focus on small-cap companies in the U.S. market. The index represents approximately 10% of the total market capitalization of the Russell 3000 Index. , the weighted average market capitalization for a company in the index is around $3.1 billion; the median market cap is $1.0 billi ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Third Rock Ventures
Third Rock Ventures is a venture capital firm based in Boston Boston (), officially the City of Boston, is the state capital and most populous city of the Commonwealth of Massachusetts, as well as the cultural and financial center of the New England region of the United States. It is the 24th- mo ..., founded in 2007According to the December 2010 edition of BoogarLists' "Venture Capital + Private Equity Directory", the inception year for the company was 2007, not 2006. — which invests in biotechnology startups. Approach Third Rock employs a four-stage approach to company creation: Discover, Launch, Build, Transform. In the Discovery phase, Third Rock works with scientific founders and expert advisors to develop a vision and strategy for a company. Once the company concept has been refined and optimized in Discovery, the firm launches the company with the necessary resources to enable it to reach critical milestones. Partners and other employees at the firm as ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Celgene
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid ( lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company PM BMS, November 20, 2019; retrieved May 20, 2020 History Celgene was originally a unit of . In 1986, Celanese co ...[...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
T Cell Receptor
The T-cell receptor (TCR) is a protein complex found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate: that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR. The TCR is composed of two different protein chains (that is, it is a heterodimer). In humans, in 95% of T cells the TCR consists of an alpha (α) chain and a beta (β) chain (encoded by '' TRA'' and ''TRB'', respectively), whereas in 5% of T cells the TCR consists of gamma and delta (γ/δ) chains (encoded by '' TRG'' and '' TRD'', respectively). This ratio changes during ontogeny and in diseased states (such as leukemia). It also differs between species. Orthologues of the 4 loci have been mapped in various species. Each locus can produce a vari ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Chimeric Antigen Receptor
In biology, chimeric antigen receptors (CARs)—also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor. CAR T cell therapy uses T cells engineered with CARs to treat cancer. The premise of CAR T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, then infuse the resulting CAR T cells into patients to attack their tumors. CAR T cells can be derived either from T cells in a patient's own blood (autologously) or from the T cells of another, healthy, donor ( allogeneically). Once isolated from a person, these T cells are genetically engineered to express a specific CAR, which programs t ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Juno Therapeutics
Juno Therapeutics Inc is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene.Bristol ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Initial Public Offering
An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors and usually also to retail (individual) investors. An IPO is typically underwritten by one or more investment banks, who also arrange for the shares to be listed on one or more stock exchanges. Through this process, colloquially known as ''floating'', or ''going public'', a privately held company is transformed into a public company. Initial public offerings can be used to raise new equity capital for companies, to monetize the investments of private shareholders such as company founders or private equity investors, and to enable easy trading of existing holdings or future capital raising by becoming publicly traded. After the IPO, shares are traded freely in the open market at what is known as the free float. Stock exchanges stipulate a minimum free float both in absolute terms (the total value as determined by the share price multiplied by the ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Business Insider
''Insider'', previously named ''Business Insider'' (''BI''), is an American financial and business news website founded in 2007. Since 2015, a majority stake in ''Business Insider''s parent company Insider Inc. has been owned by the German publishing house Axel Springer. It operates several international editions, including one in the United Kingdom. ''Insider'' publishes original reporting and aggregates material from other outlets. , it maintained a liberal policy on the use of anonymous sources. It has also published native advertising and granted sponsors editorial control of its content. The outlet has been nominated for several awards, but is criticized for using factually incorrect clickbait headlines to attract viewership. In 2015, Axel Springer SE acquired 88 percent of the stake in Insider Inc. for $343 million (€306 million), implying a total valuation of $442 million. In February 2021, the brand was renamed simply ''Insider''. History ''Busi ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Bill Gates
William Henry Gates III (born October 28, 1955) is an American business magnate and philanthropist. He is a co-founder of Microsoft, along with his late childhood friend Paul Allen. During his career at Microsoft, Gates held the positions of chairman, chief executive officer (CEO), President (corporate title), president and software architect, chief software architect, while also being the largest individual shareholder until May 2014. He was a major entrepreneur of the Home computer, microcomputer revolution of the 1970s and 1980s. Gates was born and raised in Seattle. In 1975, he and Allen founded Microsoft in Albuquerque, New Mexico. It became the world's largest personal computer software company. Gates led the company as chairman and CEO until stepping down as CEO in January 2000, succeeded by Steve Ballmer, but he remained chairman of the board of directors and became chief software architect. During the late 1990s, he was Criticism of Microsoft, criticized for his bu ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Series B
A venture round is a type of funding round used for venture capital financing, by which startup companies obtain investment, generally from venture capitalists and other institutional investors. The availability of venture funding is among the primary stimuli for the development of new companies and technologies. Features Parties *Founders or stakeholders. Introduce companies to investors. *A lead investor, typically the best known or most aggressive venture capital firm that is participating in the investment, or the one contributing the largest amount of cash. The lead investor typically oversees most of the negotiation, legal work, due diligence, and other formalities of the investment. It may also introduce the company to other investors, generally in an informal unpaid capacity. *Co-investors, other major investors who contribute alongside the lead investor *Follow-on or piggyback investors. Typically angel investors, high-net worth individuals, family offices, institut ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Simon & Schuster
Simon & Schuster () is an American publishing company and a subsidiary of Paramount Global. It was founded in New York City on January 2, 1924 by Richard L. Simon and M. Lincoln Schuster. As of 2016, Simon & Schuster was the third largest publisher in the United States, publishing 2,000 titles annually under 35 different imprints. History Early years In 1924, Richard Simon's aunt, a crossword puzzle enthusiast, asked whether there was a book of ''New York World'' crossword puzzles, which were very popular at the time. After discovering that none had been published, Simon and Max Schuster decided to launch a company to exploit the opportunity.Frederick Lewis Allen, ''Only Yesterday: An Informal History of the 1920s'', p. 165. . At the time, Simon was a piano salesman and Schuster was editor of an automotive trade magazine. They pooled , equivalent to $ today, to start a company that published crossword puzzles. The new publishing house used "fad" publishing to publish bo ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
The Code Breaker
''The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race'' is a non-fiction book authored by American historian and journalist Walter Isaacson. Published in March 2021 by Simon & Schuster, it is a biography of Jennifer Doudna, the winner of the 2020 Nobel Prize in Chemistry for her work on the CRISPR system of gene editing. The book debuted at number one on ''The New York Times'' nonfiction best-seller list for the week ending March 13, 2021. Promotion On March 22, 2021, Isaacson appeared on ''The Late Show with Stephen Colbert'' to discuss the book. Reception In its starred review, ''Kirkus Reviews'' called it a "vital book about the next big thing in science—and yet another top-notch biography from Isaacson." ''Publishers Weekly'' called it a "gripping account of a great scientific advancement and of the dedicated scientists who realized it." References External links The Code Breakerat the Simon & Schuster websiteCRISPR Scientist's ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
